Evotec SE (XBUL:EVT)
лв 8.815 0 (0%) Market Cap: 2.98 Bil Enterprise Value: 3.16 Bil PE Ratio: 0 PB Ratio: 1.56 GF Score: 66/100

Evotec SE at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 07:00PM GMT
Unidentified Analyst

Hello, everyone. Thank you for joining us. It's my pleasure to introduce, on behalf of JPMorgan, our next speaker, Werner Lanthaler. Please note that we will be hosting a Q&A session in the Kent Room after this.

With that, I will hand it over to Werner.

Werner Lanthaler
Evotec SE - CEO & Member of Management Board

Good morning. My name is Werner. I work for Evotec. Thank you for coming. As I see so many highly qualified chemists, molecular biologists in the room, I hope you don't mind that we focus this presentation more on the strategic elements of Evotec, what we as a business model represent and where the company is strategically going.

When you see the first slide of this presentation, you see Evotec is a partnered drug discovery and development company. If you think about that and if you think about this industry 20 years ago, that was not the norm because everyone did everything in their silo alone. So what we have really brought as a paradigm shift to this industry, the idea of getting more efficient, more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot